During the past decade, N.N. Blokhin NMRCO conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 3 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "N.N. Blokhin NMRCO" #1 collaborator was "Merck Sharp & Dohme LLC" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "N.N. Blokhin NMRCO" are "UC (Urothelial Cancer)" (2 trials) and "Squamous Cell Carcinoma of the Head and Neck" (1 trials). Many other conditions were trialed in "N.N. Blokhin NMRCO" in a lesser frequency.

Most popular intervention types in "N.N. Blokhin NMRCO" are "Drug" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Epacadostat" (2 trials), "Pembrolizumab" (2 trials), "Placebo" (2 trials), "Avelumab" (1 trials) and "Chemoradiation" (1 trials). Other intervention names were less common.

The vast majority of trials in "N.N. Blokhin NMRCO" are 3 trials for "All" genders.

Currently, there are NaN active trials in "N.N. Blokhin NMRCO". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in N.N. Blokhin NMRCO, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in N.N. Blokhin NMRCO, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".